In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology (KURA – Research Report), with ...

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 21.3% during the third quarter, Holdings Channel.com reports. The ...

H-pyrrolo[2,3-c]pyridine compounds acting as menin (MEN1)/MLL interaction inhibitors and thus reported to be useful for the treatment of cancer.

Fintel reports that on October 24, 2024, UBS initiated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) ...

Lomond Therapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for the treatment of hematological ...

The Manufacturers Life Insurance Company boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 16.1% in the 2nd quarter, according to the company in its most recent 13F ...

In animal models, BRM-1420 exhibited superior efficacy to both FLT3 and menin inhibitors and was shown to inhibit cell proliferation in primary AML patient samples across multiple genotypes, including ...

Mann was co-ordinator of tours and group sales at MLL from 2017 to 2019. She adjusted computer records to reflect higher passenger numbers for bus tour contractor Tony’s Team Transport ...

Mixed lineage leukaemia (MLL) and enhancer of zeste 2 (EZH2) catalyse the addition of methylation of histone H3 lysine 4 (H3K4) and H3 lysine 27 (H3K27), respectively, which are arguably two of ...